Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants

Infection and Immunity

Volumn 66, Issue 5, 1998, Pages 2093-2098

  Dagan, Ron ^a,b   Eskola, Juhani ^c   Leclerc, Claude ^d   Leroy, Odile ^e  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d INSTITUT PASTEUR   (France)

^e Pasteur Merieux Connaught   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA TOXOID; EPITOPE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PNEUMOCOCCUS VACCINE; TETANUS TOXOID;

ANTIGEN RECOGNITION; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFANT; INFECTION PREVENTION; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0031924968     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.66.5.2093-2098.1998     Document Type: Article

References (29)

1. Ahman, H., H. Käyhty, H. Lehtonen, O. Leroy, J. Froeschle, and J. Eskola. Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory. Pediatr. Infect. Dis. J., in press.
2. Ahman, H., H. Käyhty, O. Leroy, J. Froeschle, and J. Eskola. 1995. Immunogenicity of tetravalent pneumococcal (Pnc) conjugate vaccines (PncD, PncT) in Finnish infants, abstr. G69, p. 170. In Program and Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Barington, T., A. Gyhrs, K. Kristensen, and C. Heilmann. 1994. Opposite effects of actively and passively acquired immunity to the carrier on responses of human infants to a Haemophilus influenzae type b conjugate vaccine. Infect. Immun. 62:9-14.
4. Barington, T., K. Kristensen, J. Henrichsen, and C. Heilmann. 1991. Influence of prevaccination immunity on the human B-lymphocyte response to a Haemophilus influenzae type b conjugate vaccine. Infect. Immun. 59:1057-1064.
5. Barington, T., M. Skettrup, L. Juul, and C. Heilmann. 1993. Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components. Infect. Immun. 61:432-438.
6. Bloom, B. 1995. Summary: a perspective on issues relating to future vaccines. Ann. N. Y. Acad. Sci. 754:388-395.
7. Clemens, J., R. Brenner, and M. Rao. 1995. Interactions between PRP-T vaccine against Haemophilus influenzae b and conventional infant vaccines. Lessons for future studies of simultaneous immunization and combined vaccines. Ann. N. Y. Acad. Sci. 754:255-266.
8. Dagan, R., M. Muallem, R. Melamed, O. Leroy, and P. Yagupsky. 1997. Reduction of pneumococcal nasopharyngeal carriage in early infancy after immunization with tetravalent pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid. Pediatr. Infect. Dis. J. 16:1060-1064.
9. Dagan, R., R. Melamed, O. Zamir, and O. Leroy. 1997. Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigens. Pediatr Infect. Dis. J. 16:1053-1059.
10. Duncan, D. B. 1975. T-tests and intervals for comparisons suggested by the data. Biometrics 31:339-359.
11. Dunnett, C. W. 1955. A multiple comparisons procedure for comparing several treatments with a control. J. Am. Stat. Assoc. 50:1096-1121.
12. Fattom, A., Y. H. Cho, S. Fuller, and R. Naso. 1996. Overload of homologous carrier protein at the site of injection might cause a reduced immunogenicity of capsular polysaccharide conjugate vaccines, abstr. G93, p. 160. In Program and Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
13. Granoff, D. M., M. H. Rathore, S. J. Holmes, and P.D. Granoff. 1993. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines. Vaccine 11(Suppl. 1):S46-S51.
14. Greenberg, D. P., K. M. Zangwill, S. Partridge, S.-J. Chang, V. K. Wong, E. S. Curry, and J. I. Ward. 1997. Factors influencing the immunogenicity of a pneumococcal conjugate vaccine in infants. Pediatr. Res. 41:121A. (Abstract 709.)
15. Herzenberg, C. A., T. Tokuhisha, and L. A. Herzenberg. 1980. Carrier-priming leads to hapten-specific suppression. Nature 285:664-667.
16. Herzenberg, L. A., and T. Tokuhisha. 1982. Kpitope-specific regulation. I. Carrier-specific induction of suppression for IgG anti-hapten antibody responses. J. Exp. Med. 155:1730-1740.
17. Insel, R. A. 1995. Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. Ann. N. Y. Acad. Sci. 754:35-67.
18. Jensen, T., L. Galli-Stampino, S. Mouritsen, K. Frische, S. Peters, M. Meldal, and O. Werdelin. 1996. T cell recognition of Tn-glycosylated peptide antigens. Eur. J. Immunol. 26:1342-1349.
19. Kurikka, S., R.-M. Olander, and H. Käyhty. Priming with diphtheria-tetanus-pertussis vaccine enhances the response to the Haemophilus influenzae type b tetanus conjugate vaccine in infancy. Vaccine, in press.
20. + T cells prevents the induction but not the expression of carrier-induced epitopic suppression. J. Immunol. 145:1343-1349.
21. Melville-Smith, M. 1990. Diphtheria and tetanus antitoxins, p. 136-147. In T. G. Wreghitt and P. Morgan-Capner (ed.), ELISA in the clinical microbiology laboratory. Public Health Laboratory Service, London. England.
22. Mouritsen, S., M. Meldal, I. Christiansen-Brams, H. Elsner, and O. Werdelin. 1994. Attachment of oligosaccharides to peptide antigen profoundly affects binding to major histocompatibility complex class II molecules and peptide immunogenicity. Eur. J. Immunol. 24:1066-1072.
23. Peeters, C. C., A.-M. Tenbergen-Meekes, J. T. Poolman, M. Beurret, B. J. Zegers, and G. T. Rijkers. 1991. Effect of carrier priming on immunogenicity of saccharide-protein conjugate vaccines. Infect. Immun. 59:3504-3510.
24. Robbins, J. B., and R. Schneerson. 1990. Polysaccharide-protein conjugates: a new generation of vaccines. J. Infect. Dis. 161:821-832.
25. Robbins, J. B., J. C. Parke, Jr., R. Schneerson, and J. K. Whisnant. 1973. Quantitative measurement of "natural" and immunization induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr. Res. 7:103-110.
26. Schutze, M.-P., C. Leclerc, M. Jolivet, F. Audibert, and L. Chedid. 1985. Carrier-induced epitopic suppression, a major issue for future synthetic vaccines. J. Immunol. 135:2319-2322.
27. Schutze, M.-P., E. Deriaud, G. Przewlocki, and C. Leclerc. 1989. Carrier-induced epitopic suppression is initiated through clonal dominance. J. Immunol. 142:2635-2640.
28. Siber, G. R. 1994. Pneumococcal disease: prospects for a new generation of vaccines. Science 265:1385-1387.
29. Weinberg, G. A., and D. M. Granoff. 1988. Polysaccharide-protein conjugate vaccines for the prevention of Haemophilus influenzae type b disease. J. Pediatr. 113:621-631.